Drug intelligence / Profile preview

METI-201

Development stage: Preclinical
Lead developer: MetiMedi Pharmaceuticals
Administration: Oral

Overview

METI-201 is an oral functional food and nutraceutical developed by MetiMedi Pharmaceuticals for the management of inflammatory bowel disease (IBD) and other innate bowel conditions. It is designed to strengthen the NLRP-related innate immune barrier (referred to as "NLRP barriers") within the gastrointestinal tract. Unlike traditional small molecule drugs or biologics, METI-201 is categorized by its developer as a functional ingredient or "booster" intended to enhance gut health and maintain intestinal homeostasis by reinforcing the body's innate immune defenses.

Other names: METI-201 (IBD functional food)

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on METI-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METI-201.

Explore the full profile